Float Short %

29.63

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

EPS Last/This Y

0.26

EPS This/Next Y

-0.48

Price

5.7

Target Price

22.38

Analyst Recom

1.2

Performance Q

-8.36

Relative Volume

0.83

Beta

0.6

Ticker: ALT

23 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	ALT	4.61	0.24	0.05	144906
2025-04-15	ALT	4.52	0.23	0.12	148482
2025-04-16	ALT	4.41	0.22	0.37	148826
2025-04-17	ALT	4.55	0.22	0.05	151127
2025-04-18	ALT	4.55	0.22	0.05	151127
2025-04-21	ALT	4.78	0.22	0.12	142773
2025-04-22	ALT	4.84	0.22	0.15	146345
2025-04-23	ALT	4.96	0.21	0.11	149783
2025-04-24	ALT	5.16	0.21	0.02	154213
2025-04-25	ALT	5.07	0.20042735358703	0.098631040738908	162359
2025-04-28	ALT	5.06	0.1993884020138	0.27213666987488	160808
2025-04-29	ALT	5.09	0.20	0.25	164712
2025-04-30	ALT	5.23	0.20	0.21	166817
2025-05-01	ALT	5.16	0.20	0.21	168349
2025-05-02	ALT	5.77	0.20	0.19	170526
2025-05-05	ALT	5.43	0.21	0.65	166104
2025-05-06	ALT	5.03	0.23	0.22	170946
2025-05-07	ALT	5.36	0.23	0.08	175756
2025-05-08	ALT	5.8	0.23	0.16	181061
2025-05-09	ALT	5.57	0.23	2.69	185917
2025-05-12	ALT	6.02	0.37	0.97	204190
2025-05-13	ALT	5.75	0.40	0.22	212973
2025-05-14	ALT	5.72	0.39	0.40	218755
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	ALT	4.63	-0.1	-54.1	-1.09
2025-04-15	ALT	4.53	-0.1	-38.3	-1.09
2025-04-16	ALT	4.41	-0.1	-37.0	-1.09
2025-04-17	ALT	4.55	-0.1	-50.4	-1.09
2025-04-18	ALT	4.55	-0.1	-43.1	-1.09
2025-04-21	ALT	4.79	-0.1	-54.7	-1.09
2025-04-22	ALT	4.85	-0.1	-45.5	-1.09
2025-04-23	ALT	4.97	-0.1	-48.3	-1.09
2025-04-24	ALT	5.16	-0.1	-50.9	-1.09
2025-04-25	ALT	5.07	-0.1	-39.3	-1.09
2025-04-28	ALT	5.06	-0.1	-42.7	-1.09
2025-04-29	ALT	5.10	-0.1	-44.6	-1.09
2025-04-30	ALT	5.22	-0.1	-47.8	-1.09
2025-05-01	ALT	5.16	-0.1	-39.9	-1.09
2025-05-02	ALT	5.77	-0.1	-67.1	-1.09
2025-05-05	ALT	5.42	-0.1	-31.3	-1.09
2025-05-06	ALT	5.03	-0.1	-28.5	-1.09
2025-05-07	ALT	5.36	-0.1	-56.8	-1.09
2025-05-08	ALT	5.79	-0.1	-59.1	-1.09
2025-05-09	ALT	5.58	-0.1	-35.6	-1.08
2025-05-12	ALT	6.01	-0.1	-57.7	-1.08
2025-05-13	ALT	5.75	-0.5	-34.7	-1.08
2025-05-14	ALT	5.70	-0.5	-41.0	-1.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

23 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	ALT	1.39	2.52	28.63
2025-04-15	ALT	1.39	2.52	28.63
2025-04-16	ALT	1.39	2.52	28.63
2025-04-17	ALT	1.39	2.52	28.63
2025-04-18	ALT	1.39	2.52	28.63
2025-04-21	ALT	1.39	2.66	28.63
2025-04-22	ALT	1.39	2.66	28.63
2025-04-23	ALT	1.39	2.66	28.63
2025-04-24	ALT	1.39	2.66	28.63
2025-04-25	ALT	1.39	2.66	28.63
2025-04-28	ALT	1.39	2.70	29.45
2025-04-29	ALT	1.39	2.70	29.45
2025-04-30	ALT	1.39	2.70	29.45
2025-05-01	ALT	1.39	2.70	29.45
2025-05-02	ALT	1.39	2.70	29.45
2025-05-05	ALT	1.39	3.57	29.45
2025-05-06	ALT	1.39	3.57	29.45
2025-05-07	ALT	1.39	3.57	29.45
2025-05-08	ALT	1.39	3.57	29.45
2025-05-09	ALT	1.39	3.57	29.45
2025-05-12	ALT	1.39	1.85	29.63
2025-05-13	ALT	1.39	1.85	29.63
2025-05-14	ALT	1.39	1.85	29.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

23 items 1 of 1

Last Quarter Act. EPS

-0.33

Avg. EPS Est. Current Quarter

-0.37

Avg. EPS Est. Next Quarter

-0.33

Insider Transactions

1.39

Institutional Transactions

1.85

Beta

0.6

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

83.8

Max Drawdown 5-Year %

-93.6

Target Price

22.38

P/E

Forward P/E

PEG

P/S

21948.96

P/B

3.12

P/Free Cash Flow

EPS

-1.25

Average EPS Est. Cur. Y

-1.08

EPS Next Y. (Est.)

-1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-451200

Relative Volume

0.83

Return on Equity vs Sector %

-100.6

Return on Equity vs Industry %

-83.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-41

Altimmune, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

stock quote shares ALT – Altimmune, Inc. Stock Price stock today

news today ALT – Altimmune, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALT – Altimmune, Inc. yahoo finance google finance

stock history ALT – Altimmune, Inc. invest stock market

stock prices ALT premarket after hours

ticker ALT fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y